Alan Araújo de Jesus, A. Jesus, Flávia Oliveira de Lima, Luíz A. R. Freitas, Cassio S Meira, R. Ribeiro-dos-Santos, M. Soares
Autogenous bone grafting is needed in some bone tissue defects; however, it causes secondary surgical wounds and morbidity. Tissue bioengineering may be an alternative approach for bone regeneration. Here we investigated the osteogenic potential of dental pulp stem cells from deciduous teeth (DPSC) in association with a Ricinus bone compound (RBC) in a model of bone defect. The influence of the biomaterial RBC on the proliferation and osteogenic differentiation of DPSC was assessed in vitro by MTT metabolism and alizarin red staining, respectively. The morphologic analysis was performed using the optic and scanning electron (SEM) microscopies. For the in vivo study, 54 Wistar rats submitted to calvarial defects were filled with RBC or RBC+DPSC. A control group had the defects filled only with blood clots. Analyses were performed 15, 30 and 60 days after treatment using digital radiography, optical microscopy, SEM and chemical analysis by electron dispersive spectroscopy. The Ricinus bone compound (RBC) did not inhibit the osteogenic differentiation in vitro. No spontaneous regeneration was observed in the control group. The area of the calvarial defect of the RBC+DPSC group showed greater radiopacity on day 15. The RBC presented no reabsorption, was biocompatible and showed osteointegration, working as a mechanical filling. Only sparse ossification areas were found and those were larger and more developed on the RBC+DPSC group when compared to animals treated only with RBC. RBC in association with DPSC is a promising combination for applications in bone regeneration.
{"title":"Association of Dental Pulp Stem Cells and Ricinus Bone Compound in a Model of Bone Defect","authors":"Alan Araújo de Jesus, A. Jesus, Flávia Oliveira de Lima, Luíz A. R. Freitas, Cassio S Meira, R. Ribeiro-dos-Santos, M. Soares","doi":"10.34178/jbth.v3i3.129","DOIUrl":"https://doi.org/10.34178/jbth.v3i3.129","url":null,"abstract":"Autogenous bone grafting is needed in some bone tissue defects; however, it causes secondary surgical wounds and morbidity. Tissue bioengineering may be an alternative approach for bone regeneration. Here we investigated the osteogenic potential of dental pulp stem cells from deciduous teeth (DPSC) in association with a Ricinus bone compound (RBC) in a model of bone defect. The influence of the biomaterial RBC on the proliferation and osteogenic differentiation of DPSC was assessed in vitro by MTT metabolism and alizarin red staining, respectively. The morphologic analysis was performed using the optic and scanning electron (SEM) microscopies. For the in vivo study, 54 Wistar rats submitted to calvarial defects were filled with RBC or RBC+DPSC. A control group had the defects filled only with blood clots. Analyses were performed 15, 30 and 60 days after treatment using digital radiography, optical microscopy, SEM and chemical analysis by electron dispersive spectroscopy. The Ricinus bone compound (RBC) did not inhibit the osteogenic differentiation in vitro. No spontaneous regeneration was observed in the control group. The area of the calvarial defect of the RBC+DPSC group showed greater radiopacity on day 15. The RBC presented no reabsorption, was biocompatible and showed osteointegration, working as a mechanical filling. Only sparse ossification areas were found and those were larger and more developed on the RBC+DPSC group when compared to animals treated only with RBC. RBC in association with DPSC is a promising combination for applications in bone regeneration. \u0000 ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125808920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISI-SENAI-CIMATEC Group, Development and Innovation Laboratory of Butantan
Scientists, health organizations, and pharmaceutical companies are making a large global effort to develop vaccines against SARS-CoV-2, the virus of COVID-19 since the outbreak began. Until now, we have more than 150 candidates. However, 19 vaccine candidates have entered clinical trials in phase 2 and 3 trials (31 July 2020). In this article we aimed to present the platforms for COVID-19 vaccine, the types of vaccines (live, attenuated, inactivated, DNA/RNA, proteins subunits, viral vector), the antigen selection, adjuvants, and we focused on the phase 2/3 trial vaccines at this point (Sinopharm, Coronavac, Moderna, Oxford, Biontech). We searched the data in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We reviewed 216 articles and used 106 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, vaccine, platform, antigen, subunit, live and attenuated vaccine, RNA vaccine, live vaccine, inactivated vaccine, types of vaccines, adjuvants, replication, viral vector, phase 1-3, trial, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that although vaccines have shown safety in phase 1 and efficacy in phase 2 and the beginning of phase 3 is starting, the most renowned scientists believe that a vaccine will be available only in the middle of next year.
科学家、卫生组织和制药公司正在全球范围内大力开发针对新冠病毒(SARS-CoV-2)的疫苗。到目前为止，我们有150多名候选人。然而，19种候选疫苗已进入二期和三期临床试验(2020年7月31日)。在本文中，我们旨在介绍COVID-19疫苗的平台、疫苗类型(活疫苗、减毒疫苗、灭活疫苗、DNA/RNA疫苗、蛋白质亚基疫苗、病毒载体疫苗)、抗原选择、佐剂，并重点介绍了目前2/3期试验疫苗(国药、冠华、Moderna、Oxford、Biontech)。我们检索了主数据库(PubMed/Medline、Elsevier Science Direct、Scopus、Isi Web of Science、Embase、摘录Medica、UptoDate、丁香、爱思唯尔新型冠状病毒资源目录)和高影响力国际科学期刊(Scimago Journal和Country Rank - SJR - and Journal Citation Reports - JCR)的数据，如the Lancet、Science、Nature、the New England Journal of Medicine、Physiological Reviews、Journal of American Medical Association、Plos One、《临床调查杂志》，数据来自美国疾病控制中心(CDC)、美国国立卫生研究院(NIH)、美国国家过敏和传染病研究所(NIAID)和世界卫生组织(WHO)。我们之前按照这个顺序选择了meta分析、系统综述、文章综述和原创文章。我们从2020年3月至6月共检索了216篇文献，其中收录了106篇，检索条目包括:冠状病毒、SARS-CoV-2、新型冠状病毒、武汉冠状病毒、严重急性呼吸综合征、2019- ncov、2019新型冠状病毒、n-CoV-2、covid、n-SARS-2、covid、冠状病毒、冠状病毒、疫苗、平台、抗原、亚基、活疫苗和减毒疫苗、RNA疫苗、活疫苗、灭活疫苗、疫苗类型、佐剂、复制、病毒载体、1-3期、试验、使用工具MeSH(医学主题标题)、AND、OR和字符[，"，;/。，确保最佳的复习题目。我们的结论是，虽然疫苗在第一阶段显示出安全性，在第二阶段显示出有效性，并且正在开始第三阶段，但最知名的科学家认为，疫苗要到明年年中才能问世。
{"title":"Vaccines’ Candidates Against SARS-CoV-2","authors":"ISI-SENAI-CIMATEC Group, Development and Innovation Laboratory of Butantan ","doi":"10.34178/jbth.v3i2.126","DOIUrl":"https://doi.org/10.34178/jbth.v3i2.126","url":null,"abstract":"Scientists, health organizations, and pharmaceutical companies are making a large global effort to develop vaccines against SARS-CoV-2, the virus of COVID-19 since the outbreak began. Until now, we have more than 150 candidates. However, 19 vaccine candidates have entered clinical trials in phase 2 and 3 trials (31 July 2020). In this article we aimed to present the platforms for COVID-19 vaccine, the types of vaccines (live, attenuated, inactivated, DNA/RNA, proteins subunits, viral vector), the antigen selection, adjuvants, and we focused on the phase 2/3 trial vaccines at this point (Sinopharm, Coronavac, Moderna, Oxford, Biontech). We searched the data in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We reviewed 216 articles and used 106 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, vaccine, platform, antigen, subunit, live and attenuated vaccine, RNA vaccine, live vaccine, inactivated vaccine, types of vaccines, adjuvants, replication, viral vector, phase 1-3, trial, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that although vaccines have shown safety in phase 1 and efficacy in phase 2 and the beginning of phase 3 is starting, the most renowned scientists believe that a vaccine will be available only in the middle of next year. \u0000 ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128639368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISI-SENAI-CIMATEC Group, Development and Innovation Laboratory of Butantan
There is no specific drug or therapy against COVID-19. Since the beginning of the pandemic, scientists are running to discover a drug or therapy that can treat the disease. What we found until now are a combined drug and therapies that can mitigate the effects of the disease in the human body and how to manage the patient better. In this article, we tried to join the new discoveries and presented the drugs and therapies and their mechanisms to combat the SARS-CoV-2. We showed the immunomodulators, parasiticides, antiviral drugs (focused on Remdesivir), antimalarial drugs, anti-cytokine drugs focused on the role of IL-6, Reumathological drugs, inhibitors of cell-receptors, antiinflammatory drugs, especially the role of corticosteroids (dexamethasone), antibiotics (azithromycin), anti-thrombotic drugs, blood derivates therapies and alternative therapies currently used against COVID-19. Also, we listed the main results of clinical trials of new therapies presented by Recommended Panel Treatment Guidelines [NIAID-RML (USA)]. We searched the data in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We used 302 articles from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, immunomodulators, parasiticides, antiviral, antimalarial, anti-thrombotic and anti-cytokine, antiinflammatory, Reumathological drugs, inhibitors of cell-receptors, antibiotics, blood derivates therapies and alternative therapies, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that despite there is no treatment or drugs against the COVID-19, a combined therapy can help and mitigate the effects of the disease, helping the immune system to combat the virus.
目前还没有针对COVID-19的特异性药物或治疗方法。自大流行开始以来，科学家们一直在努力发现一种可以治疗这种疾病的药物或疗法。到目前为止，我们发现的是一种药物和疗法的结合，可以减轻这种疾病对人体的影响，以及如何更好地管理病人。在本文中，我们试图加入新的发现，并介绍了对抗SARS-CoV-2的药物和疗法及其机制。我们展示了免疫调节剂、杀寄生虫剂、抗病毒药物(主要是雷姆德西韦)、抗疟疾药物、主要是IL-6作用的抗细胞因子药物、风湿病药物、细胞受体抑制剂、抗炎药物，特别是皮质类固醇(地塞米松)、抗生素(阿奇霉素)、抗血栓形成药物、血液衍生物疗法和目前用于COVID-19的替代疗法。此外，我们还列出了推荐小组治疗指南[NIAID-RML (USA)]中提出的新疗法临床试验的主要结果。我们检索了主数据库(PubMed/Medline、Elsevier Science Direct、Scopus、Isi Web of Science、Embase、摘录Medica、UptoDate、丁香、爱思唯尔新型冠状病毒资源目录)和高影响力国际科学期刊(Scimago Journal和Country Rank - SJR - and Journal Citation Reports - JCR)的数据，如the Lancet、Science、Nature、the New England Journal of Medicine、Physiological Reviews、Journal of American Medical Association、Plos One、《临床调查杂志》，数据来自美国疾病控制中心(CDC)、美国国立卫生研究院(NIH)、美国国家过敏和传染病研究所(NIAID)和世界卫生组织(WHO)。我们之前按照这个顺序选择了meta分析、系统综述、文章综述和原创文章。我们使用了2020年3月至6月的302篇文章，使用了以下术语:冠状病毒、SARS-CoV-2、新型冠状病毒、武汉冠状病毒、严重急性呼吸综合征、2019- ncov、2019新型冠状病毒、n-CoV-2、covid、n-SARS-2、covid、冠状病毒、冠状病毒、免疫调节剂、抗寄生虫剂、抗病毒药物、抗疟疾药物、抗血栓形成和抗细胞因子、抗炎药、风湿病药物、细胞受体抑制剂、抗生素、血液衍生物疗法和替代疗法。使用工具MeSH(医学主题标题)、AND、OR和字符[，"，;/。，确保最佳的复习题目。我们的结论是，尽管没有针对COVID-19的治疗方法或药物，但联合治疗可以帮助减轻疾病的影响，帮助免疫系统对抗病毒。
{"title":"Therapies Against COVID-19: a Running to a Treatment","authors":"ISI-SENAI-CIMATEC Group, Development and Innovation Laboratory of Butantan ","doi":"10.34178/jbth.v3i2.125","DOIUrl":"https://doi.org/10.34178/jbth.v3i2.125","url":null,"abstract":"There is no specific drug or therapy against COVID-19. Since the beginning of the pandemic, scientists are running to discover a drug or therapy that can treat the disease. What we found until now are a combined drug and therapies that can mitigate the effects of the disease in the human body and how to manage the patient better. In this article, we tried to join the new discoveries and presented the drugs and therapies and their mechanisms to combat the SARS-CoV-2. We showed the immunomodulators, parasiticides, antiviral drugs (focused on Remdesivir), antimalarial drugs, anti-cytokine drugs focused on the role of IL-6, Reumathological drugs, inhibitors of cell-receptors, antiinflammatory drugs, especially the role of corticosteroids (dexamethasone), antibiotics (azithromycin), anti-thrombotic drugs, blood derivates therapies and alternative therapies currently used against COVID-19. Also, we listed the main results of clinical trials of new therapies presented by Recommended Panel Treatment Guidelines [NIAID-RML (USA)]. We searched the data in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We used 302 articles from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, immunomodulators, parasiticides, antiviral, antimalarial, anti-thrombotic and anti-cytokine, antiinflammatory, Reumathological drugs, inhibitors of cell-receptors, antibiotics, blood derivates therapies and alternative therapies, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that despite there is no treatment or drugs against the COVID-19, a combined therapy can help and mitigate the effects of the disease, helping the immune system to combat the virus. \u0000 ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126307200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this review article, we presented a gold-standard method to detect the SARS-CoV-2, the novel virus that is causing the COVID-19 outbreak, and the use of a computer tomography (CT) method to detect the complications of the disease. We showed the controversial analysis about which method is the best to detect the disease earlier due to the COVID-19 complications. We searched the articles in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We reviewed 96 articles and used 45 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, RT-PCR, computer tomography (CT), diagnostic methods, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that chest CT plays an important role in the timely detection of lung infection abnormalities in the early phase of COVID-19 infection. However, the RT-PCR is the gold standard method to detect SARS-CoV-2.
在这篇综述文章中，我们提出了一种检测导致COVID-19爆发的新型病毒SARS-CoV-2的金标准方法，并使用计算机断层扫描(CT)方法检测该疾病的并发症。我们展示了由于COVID-19并发症，哪种方法最能早期发现疾病的争议分析。我们检索了主数据库(PubMed/Medline、Elsevier Science Direct、Scopus、Isi Web of Science、Embase、摘录医学、UptoDate、丁香、爱思唯尔新型冠状病毒资源目录)和高影响力国际科学期刊(Scimago Journal和Country Rank - SJR - and Journal Citation Reports - JCR)中的文章，如《柳叶刀》、《科学》、《自然》、《新英格兰医学杂志》、《生理评论》、《美国医学协会杂志》、《Plos One》、《临床调查杂志》，数据来自美国疾病控制中心(CDC)、美国国立卫生研究院(NIH)、美国国家过敏和传染病研究所(NIAID)和世界卫生组织(WHO)。我们之前按照这个顺序选择了meta分析、系统综述、文章综述和原创文章。我们查阅了2020年3月至6月的96篇论文，其中45篇使用了冠状病毒、SARS-CoV-2、新型冠状病毒、武汉冠状病毒、严重急性呼吸综合征、2019- ncov、2019-新型冠状病毒、n-CoV-2、covid、n-SARS-2、covid、冠状病毒、冠状病毒、RT-PCR、计算机断层扫描(CT)、诊断方法，使用了MeSH(医学主题词)、and、OR和字符[，"，;/．，确保最佳的复习题目。综上所述，胸部CT在COVID-19感染早期及时发现肺部感染异常方面具有重要作用。然而，RT-PCR是检测SARS-CoV-2的金标准方法。
{"title":"Diagnostic of COVID-19: Chest Computer Tomography or RT-PCR?","authors":"ISI-SENAI-CIMATEC Group","doi":"10.34178/jbth.v3i2.124","DOIUrl":"https://doi.org/10.34178/jbth.v3i2.124","url":null,"abstract":"In this review article, we presented a gold-standard method to detect the SARS-CoV-2, the novel virus that is causing the COVID-19 outbreak, and the use of a computer tomography (CT) method to detect the complications of the disease. We showed the controversial analysis about which method is the best to detect the disease earlier due to the COVID-19 complications. We searched the articles in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We reviewed 96 articles and used 45 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, RT-PCR, computer tomography (CT), diagnostic methods, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that chest CT plays an important role in the timely detection of lung infection abnormalities in the early phase of COVID-19 infection. However, the RT-PCR is the gold standard method to detect SARS-CoV-2. \u0000 ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114832813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Appendix 1: EUA Case Study Database WHO Case Study Database","authors":"ISI-SENAI-CIMATEC Group","doi":"10.34178/jbth.v3ia1.127","DOIUrl":"https://doi.org/10.34178/jbth.v3ia1.127","url":null,"abstract":"This Appendix 1 presents the clinical trials against COVID-19 registered in WHO and clinicaltrials.gov by United States of America database.","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115337437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This special edition of the Journal of Bioengineering and Technology Applied to Health brings a second selection of articles presented at the VI International Symposium on Innovation and Technology (SIINTEC). The SIINTEC happens since 2015. The event is annual and promoted by SENAI CIMATEC, Salvador, Bahia, Brazil. The VI SIINTEC focused on discussing challenges in science, technology, and innovation after COVID-19.
{"title":"Contributions and Impacts on Health Using New Technologies and Innovative Products","authors":"L. Guarieiro, A. A. Santos","doi":"10.34178/JBTH.V4I1.146","DOIUrl":"https://doi.org/10.34178/JBTH.V4I1.146","url":null,"abstract":"This special edition of the Journal of Bioengineering and Technology Applied to Health brings a second selection of articles presented at the VI International Symposium on Innovation and Technology (SIINTEC). The SIINTEC happens since 2015. The event is annual and promoted by SENAI CIMATEC, Salvador, Bahia, Brazil. The VI SIINTEC focused on discussing challenges in science, technology, and innovation after COVID-19. \u0000 \u0000 ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115510760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lílian Lefol Nani Guarieiro, Alex Álisson Bandeira Santos
This edition of the Journal of Bioengineering and Technology Applied to Health brings a selection of four articles presented at the V International Symposium on Innovation and Technology (SIINTEC)-2019.
《应用于健康的生物工程与技术杂志》精选了2019年第五届国际创新与技术研讨会上发表的四篇文章。
{"title":"Contributions and Impacts on Health Using New Technologies and Innovative Products","authors":"Lílian Lefol Nani Guarieiro, Alex Álisson Bandeira Santos","doi":"10.34178/jbth.v2i4.88","DOIUrl":"https://doi.org/10.34178/jbth.v2i4.88","url":null,"abstract":"This edition of the Journal of Bioengineering and Technology Applied to Health brings a selection of four articles presented at the V International Symposium on Innovation and Technology (SIINTEC)-2019.","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"225 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123638239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A lot of countries have difficulty in combating Ae. aegypti, due to the high adaptability of this mosquito to the urban area. The National Program for Dengue Control (PNCD) is responsible for allocating the most activities to combat Ae. aegypti in districts of Brazil (basic sanitation, education, chemical control). Despite the technological advances in the 21th century, there was little social commitment with the conception of a formal device in the fight against Ae. aegypti. Senai-Cimatec developed a trap (Lethal Ovitrap CimatecTM) based on new technologies to control Aedes aegypti. So, the aim of this study was to compare the traditional traps on the market with the LOCTM trap, created by Cimatec. We performed two experiments to evaluate the performance of the traps against the mosquitoes. The tests occurred in a monitored and closed environment at the Central Laboratory of Bahia (Entomology Laboratory) (LACEN/BA). The larvae, water, and substrate for the experiment in the three containers had the same origin; three cages were kept in the entomology sector with the same conditions of temperature and humidity. The results showed that LOCTM has several advantages when compared to the traditional traps, such as: capacity to eliminate the immature forms of the vector in a few hours; entrapment and extermination of larvae and/or adults forms by asphyxiation; high lethality for mosquitoes and ability to reduce the Aedes population in an area by removing from the environment future generations of mosquitoes; installation; it is attractive to mosquitoes; no needs of weekly monitoring; no power consumption; simple manipulation and low-cost; water as a protection factor and not as a risk factor; it does not use insecticide or any toxic agent harmful to human health. So, the use of LOCTM has advantages over traditional traps, directing the biotechnology market to new solutions with low-cost, easy to handle and non-toxic to man and the environment in the fight agains Ae. aegypti
{"title":"Lethal Ovitrap CIMATEC: A New Trap for Arbovirus Transmitting Mosquitoes","authors":"E. Oyama, D. Mota","doi":"10.34178/jbth.v2i2.56","DOIUrl":"https://doi.org/10.34178/jbth.v2i2.56","url":null,"abstract":"A lot of countries have difficulty in combating Ae. aegypti, due to the high adaptability of this mosquito to the urban area. The National Program for Dengue Control (PNCD) is responsible for allocating the most activities to combat Ae. aegypti in districts of Brazil (basic sanitation, education, chemical control). Despite the technological advances in the 21th century, there was little social commitment with the conception of a formal device in the fight against Ae. aegypti. Senai-Cimatec developed a trap (Lethal Ovitrap CimatecTM) based on new technologies to control Aedes aegypti. So, the aim of this study was to compare the traditional traps on the market with the LOCTM trap, created \u0000by Cimatec. We performed two experiments to evaluate the performance of the traps against the mosquitoes. The tests occurred in a monitored and closed environment at the Central Laboratory of Bahia (Entomology Laboratory) (LACEN/BA). The larvae, water, and substrate for the experiment in the three containers had the same origin; three cages were kept in the entomology sector with the same conditions of temperature and humidity. The results showed that LOCTM has several advantages when compared to the traditional traps, such as: capacity to eliminate the immature forms of the vector in a few hours; entrapment and extermination of larvae and/or adults forms by asphyxiation; high lethality for mosquitoes and ability to reduce the Aedes population in an area by removing from the environment future generations of mosquitoes; installation; it is attractive to mosquitoes; no needs of weekly monitoring; no power consumption; simple manipulation and low-cost; water as a protection factor and not as a risk factor; it does not use insecticide or any toxic agent harmful to human health. So, the use of LOCTM has advantages over traditional traps, directing the biotechnology market to new solutions with low-cost, easy to handle and non-toxic to man and the environment in the fight agains Ae. aegypti","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120923678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The technological advances of recent decades in immunodiagnostic techniques have enabled the development of methods capable of detecting the antigen-antibody complex with high efficiency and reliability. However, the cost of such procedures has remained high; they are not easy to handle for an unskilled professional, nor provide immediate results for multiple samples. Precision Photonics Corporation (PPC), with m/Bio Inc. and in partnership with the University of San Diego (UCSD), USA, created an integrated circuit reader (Biochip Reader), which is low cost, fast and easy to handle, based on an optical systems and multiplex arrangements for the detection of biological multi-markers at the same time. This study aimed to evaluate the operation of the integrated circuit reader system (Biochip Reader), the protocols and the results of the multiplex tests for antibodies against HIV and HCV in partnership with the Federal University of Bahia (UFBA). We tested a total of 65 samples in the Biochip reader, and they showed 100% of sensitivity and specificity when compared to the results obtained by ELISA for HIV and HCV. Nevertheless, the protocols and the results obtained in Bahia presented slide instability, such as the formation of crystals and trehalose residues, unnecessary steps and manipulation of the slides. This fact led to changing the protocol and improving the prototype. However, more tests with new biomarkers are needed to validate the method.
{"title":"Evaluation of PPC / mBio Inc.’s Biochip Reader Integrated Circuit Reader System for Diagnosis of HIV / HCV Infection: Preliminary Method","authors":"L. Knop, R. Badaró, Chris Myat","doi":"10.34178/jbth.v2i1.49","DOIUrl":"https://doi.org/10.34178/jbth.v2i1.49","url":null,"abstract":"The technological advances of recent decades in immunodiagnostic techniques have enabled the development of methods capable of detecting the antigen-antibody complex with high efficiency and reliability. However, the cost of such procedures has remained high; they are not easy to handle for an unskilled professional, nor provide immediate results for multiple samples. Precision Photonics Corporation (PPC), with m/Bio Inc. and in partnership with the University of San Diego (UCSD), USA, created an integrated circuit reader (Biochip Reader), which is low cost, fast and easy to handle, based on an optical systems and multiplex arrangements for the detection of biological multi-markers at the same time. This study aimed to evaluate the operation of the integrated circuit reader system (Biochip Reader), the protocols and the results of the multiplex tests for antibodies against HIV and HCV in partnership with the Federal University of Bahia (UFBA). We tested a total of 65 samples in the Biochip reader, and they showed 100% of sensitivity and specificity when compared to the results obtained by ELISA for HIV and HCV. Nevertheless, the protocols and the results obtained in Bahia presented slide instability, such as the formation of crystals and trehalose residues, unnecessary steps and manipulation of the slides. This fact led to changing the protocol and improving the prototype. However, more tests with new biomarkers are needed to validate the method.","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132704297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mosquito Zero is an application that is designed to demonstrate the efficiency and effectiveness of information, education and communication between public authorities and citizens regarding Aedes aegypti, the diseases this mosquito transmits and the health impacts, providing citizens with a smooth and accessible channel of communication about the mosquito and arboviruses through the application and virtual robots.
{"title":"Mosquito ZeroTM","authors":"Alex Sandro Correia","doi":"10.34178/jbth.v2i1.53","DOIUrl":"https://doi.org/10.34178/jbth.v2i1.53","url":null,"abstract":"Mosquito Zero is an application that is designed to demonstrate the efficiency and effectiveness of information, education and communication between public authorities and citizens regarding Aedes aegypti, the diseases this mosquito transmits and the health impacts, providing citizens with a smooth and accessible channel of communication about the mosquito and arboviruses through the application and virtual robots.","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122374020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：